Literature DB >> 15009674

Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones.

L R Fodero1, S S Mok, D Losic, L L Martin, M I Aguilar, C J Barrow, B G Livett, D H Small.   

Abstract

The beta-amyloid protein (Abeta) is the major protein component of amyloid plaques found in the Alzheimer brain. Although there is a loss of acetylcholinesterase (AChE) from both cholinergic and non-cholinergic neurones in the brain of Alzheimer patients, the level of AChE is increased around amyloid plaques. Previous studies using P19 cells in culture and transgenic mice which overexpress human Abeta have suggested that this increase may be due to a direct action of Abeta on AChE expression in cells adjacent to amyloid plaques. The aim of the present study was to examine the mechanism by which Abeta increases levels of AChE in primary cortical neurones. Abeta1-42 was more potent than Abeta1-40 in its ability to increase AChE in primary cortical neurones. The increase in AChE was unrelated to the toxic effects of the Abeta peptides. The effect of Abeta1-42 on AChE was blocked by inhibitors of alpha7 nicotinic acetylcholine receptors (alpha7 nAChRs) as well as by inhibitors of L- or N-type voltage-dependent calcium channels (VDCCs), whereas agonists of alpha7 nAChRs (choline, nicotine) increased the level of AChE. The results demonstrate that the effect of Abeta1-42 on AChE is due to an agonist effect of Abeta1-42 on the alpha7 nAChR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009674     DOI: 10.1046/j.1471-4159.2003.02296.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

Review 1.  Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Authors:  Daniela Puzzo; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 2.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 3.  The keystone of Alzheimer pathogenesis might be sought in Aβ physiology.

Authors:  D Puzzo; W Gulisano; O Arancio; A Palmeri
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 4.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

5.  Regional acetylcholinesterase activity and its correlation with behavioral performances in 15-month old transgenic mice expressing the human C99 fragment of APP.

Authors:  M Dumont; R Lalonde; J-F Ghersi-Egea; K Fukuchi; C Strazielle
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

Review 6.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

7.  Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission.

Authors:  Saak V Ovsepian; Valerie B O'Leary; Laszlo Zaborszky
Journal:  Neuroscientist       Date:  2015-05-22       Impact factor: 7.519

Review 8.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

Review 9.  Amyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's disease.

Authors:  Elena Anahi Bignante; Florencia Heredia; Gerardo Morfini; Alfredo Lorenzo
Journal:  Neurobiol Aging       Date:  2013-05-25       Impact factor: 4.673

10.  Upregulation of alpha7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides.

Authors:  Cherie E Bond; Martina Zimmermann; Susan A Greenfield
Journal:  PLoS One       Date:  2009-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.